We also identified a 4-marker biosignature consisting of EGF, IL-15, MIP-1β and TNF-β that could differentiate TB patients into slow or fast treatment responders at baseline in relation to smear or culture outcome at 2-months with a sensitivity of 75% and specificity of 80%. The gene discussed is LTA; the disease is tuberculosis.